Sign In
Buy ILMN
$168.06
-2.87 (-1.68%)
At Close: Jun 04, 2026
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics
08:00am, Saturday, 06'th May 2023
Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.
Why Illumina Fell 11.6% in April
07:24am, Saturday, 06'th May 2023
Illumina announced a downbeat set of earnings for its fiscal 2023 first quarter. The company received more than 200 orders for its new NovaSeq X instrument from customers in almost 30 countries.
Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
07:24am, Wednesday, 03'rd May 2023
The phrase, “I'm from the government and I'm here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. NASDAQ: ILMN, which specializes in DNA se
Icahn Writes Another Open Letter to Illumina Shareholders
06:20pm, Tuesday, 02'nd May 2023
Sunny Isles Beach, Florida, May 1, 2023 — Today, Carl C. Icahn released the following open letter to the shareholders of Illumina, Inc. ( ILMN , Financial).
Illumina: Icahn's nominees ‘unqualified'
03:21pm, Monday, 01'st May 2023
Illumina Inc. ILMN said Monday that activist investor Carl Icahn's board nominees are “unqualified,” urging shareholders to reject all three of Icahn's nominees and instead support its “highly q
4 More Undervalued Stocks to Buy After | May 1, 2023
09:16am, Monday, 01'st May 2023
#Morningstar #StockMarket #Investing Plus what the Federal Reserve meeting may mean for markets this week. Every Monday morning, Susan Dziubinski sits down with Morningstar Chief U.S. markets strategi
Carl Icahn calls Illumina Q1 results ‘very disappointing,' slams cost-cutting plan
02:35pm, Friday, 28'th Apr 2023
Activist investor Carl Icahn accused Illumina CEO Francis deSouza of trying to downplay the company's "decidedly mediocre" Q1 2023 results this week.
Critical-rated security flaw in Illumina DNA sequencing tech exposes patient data
11:15am, Friday, 28'th Apr 2023
The U.S. government has sounded the alarm about a critical software vulnerability found in genomics giant Illumina's DNA sequencing devices, which hackers can exploit to modify or steal patients' sens
Illumina CEO touts Grail's 100% revenue growth amid proxy fight with Icahn
02:26pm, Wednesday, 26'th Apr 2023
CEO Francis deSouza said San Diego-based Illumina can significantly expand the market for Grail's early cancer screening test.
Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
10:40am, Wednesday, 26'th Apr 2023
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
Illumina CEO Francis deSouza on Q1 earnings, Grail acquisition
09:14am, Wednesday, 26'th Apr 2023
Illumina CEO Francis deSouza joins 'Squawk Box' to discuss Q1 earnings results, the company's Grail acquisition challenge, the future of DNA sequencing, and more.
Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
09:17pm, Tuesday, 25'th Apr 2023
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare
Illumina, Inc. (ILMN) Q1 2023 Earnings Call Transcript
08:46pm, Tuesday, 25'th Apr 2023
Illumina, Inc. (ILMN) Q1 2023 Earnings Call Transcript.
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
06:59pm, Tuesday, 25'th Apr 2023
Illumina (ILMN) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $1.07 per share a year ago.
Illumina unveils plans to cut costs as it faces shrinking margins
05:13pm, Tuesday, 25'th Apr 2023
The plans aim to reduce Illumina's annualized run rate expenses by more than $100 million starting later this year.
